Literature DB >> 15550293

The neuropsychiatry of Parkinson's disease and related disorders.

Edward C Lauterbach1.   

Abstract

Parkinson's disease is associated with classical Parkinsonian features that respond to dopaminergic therapy. Neuropsychiatric sequelae include dementia, major depression, dysthymia, anxiety disorders, sleep disorders, and sexual disorders. Panic attacks are particularly common. With treatment, visual hallucinations, paranoid delusions, mania, or delirium may evolve. Psychosis is a key factor in nursing home placement, and depression is the most significant predictor of quality of life. Clozapine may be the safest treatment for psychotic features, but more research is needed to establish the efficacy of antidepressant treatments. Dementia with Lewy bodies, the second most common dementia in the elderly, may present in association with systematized delusions, depression, or RBD. Early evidence suggests the utility of rivastigmine, donepezil, low-dose olanzapine, and quetiapine in treating DLB. Parkinson-plus syndromes generally lack a good response to dopaminergic treatment and evidence additional features, including dysautonomia, cerebellar and pontine features, eye signs, and other movement disorders. MSA is associated with dysautonomia and RBD. SND (MSA-P) is associated with frontal cognitive impairments, but dementia, psychosis, and mood disorders have not been strikingly apparent unless additional pathological findings are present. In SDS (MSA-A), impotence is almost ubiquitous; urinary incontinence is frequent; depression is occasional, and sleep apnea should be treated to avoid sudden death during sleep. OPCA neuropsychiatric correlates await further definition. Progressive supranuclear palsy neuropsychiatric features include apathy, subcortical dementia, pathological emotionality, mild depression and anxiety, and lack of appreciable response to donepezil. CBD usually is recognized by early frontal dementia with ideomotor apraxia, often in the right upper extremity, attended later by poorly responsive unilateral Parkinsonism, with additional signs including cortical reflex myoclonus, limb dystonia, alien limb, oculomotor apraxia when asked to look horizontally, depression, personality changes, and, occasionally, Kluver-Bucy syndrome. The neuropsychiatry of FTDP-17 involves apraxia, executive impairment, personality changes, hyperorality, and occasional psychosis. Future research in these Parkinsonian disorders should target the characterization of neuropsychiatric sequelae and their treatment.

Entities:  

Mesh:

Year:  2004        PMID: 15550293     DOI: 10.1016/j.psc.2004.07.001

Source DB:  PubMed          Journal:  Psychiatr Clin North Am        ISSN: 0193-953X


  21 in total

1.  Frequency and correlates of co-morbid psychosis and depression in Parkinson's disease.

Authors:  Daniel Weintraub; Knashawn H Morales; John E Duda; Paul J Moberg; Matthew B Stern
Journal:  Parkinsonism Relat Disord       Date:  2006-06-22       Impact factor: 4.891

Review 2.  Apathy in neuropsychiatric disease: diagnosis, pathophysiology, and treatment.

Authors:  Thomas N Chase
Journal:  Neurotox Res       Date:  2010-05-15       Impact factor: 3.911

3.  Patterns of focal gray matter atrophy are associated with bradykinesia and gait disturbances in older adults.

Authors:  Caterina Rosano; David A Bennett; Anne B Newman; Vijay Venkatraman; Kristine Yaffe; Tamara Harris; Stephen Kritchevsky; Howard J Aizenstein
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-02-24       Impact factor: 6.053

4.  Dopaminergic Medication in Parkinson's Disease and Problem Gambling.

Authors:  Jacqueline Olley; Alex Blaszczynski; Simon Lewis
Journal:  J Gambl Stud       Date:  2015-09

Review 5.  [Parkinson's disease and psychoses].

Authors:  Jacopo Vittoriano Bizzarri; Giancarlo Giupponi; Ignazio Maniscalco; Patrizia Schroffenegger; Andreas Conca; Hans Peter Kapfhammer
Journal:  Neuropsychiatr       Date:  2015-01-14

Review 6.  Synucleinopathies: common features and hippocampal manifestations.

Authors:  Weiwei Yang; Shun Yu
Journal:  Cell Mol Life Sci       Date:  2016-11-08       Impact factor: 9.261

7.  Depression Screening from Voice Samples of Patients Affected by Parkinson's Disease.

Authors:  Yasin Ozkanca; Miraç Göksu Öztürk; Merve Nur Ekmekci; David C Atkins; Cenk Demiroglu; Reza Hosseini Ghomi
Journal:  Digit Biomark       Date:  2019-06-12

8.  Cognitive and neuropsychiatric profile of the synucleinopathies: Parkinson disease, dementia with Lewy bodies, and multiple system atrophy.

Authors:  Aimee W Kao; Caroline A Racine; Lovingly C Quitania; Joel H Kramer; Chadwick W Christine; Bruce L Miller
Journal:  Alzheimer Dis Assoc Disord       Date:  2009 Oct-Dec       Impact factor: 2.703

9.  Suicidal and death ideation in Parkinson's disease.

Authors:  Sarra Nazem; Andrew D Siderowf; John E Duda; Gregory K Brown; Tom Ten Have; Matthew B Stern; Daniel Weintraub
Journal:  Mov Disord       Date:  2008-08-15       Impact factor: 10.338

10.  Use of latent variable modeling to delineate psychiatric and cognitive profiles in Parkinson disease.

Authors:  Shahrzad Mavandadi; Sarra Nazem; Thomas R Ten Have; Andrew D Siderowf; John E Duda; Matthew B Stern; Daniel Weintraub
Journal:  Am J Geriatr Psychiatry       Date:  2009-11       Impact factor: 4.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.